CA
NZ
UK
AU
IND
US
The Supreme Court’s refusal to hear appeals from Novo Nordisk, AstraZeneca (LSE: AZN), Bristol-Myers Squibb Company (NYSE: BMY), Johnson &Amp; Johnson (NYSE: JNJ), Merck & Co Inc. (NYSE: MRK) and Boehringer Ingelheim signals the end of Big Pharma’s legal campaign against the Inflation Reduction …
Tarsus Pharmaceuticals (NASDAQ: TARS) is a late-stage biopharmaceutical company focused on the discovery, development, and commercialisation of therapies for ophthalmic and dermatologic diseases. Headquartered in Irvine, California, and listed on the NASDAQ exchange, Tarsus operates primarily in the United States—a market where eye-care specialists, …
CG Life is a full-service rare-diseaseMarketingagency owned by Carlyle Group Inc (Nasdaq: CG), a global alternative-asset manager with aMarket Capitalisationof $16.3bn. The agency craftsBrandcampaigns for therapies targeting ultra-orphan indications, where patient populations can number in the thousands and premium pricing is the norm. Rare-disease …
Novartis has escalated a commercial spat with Porton Pharma Solutions by terminating a plant contract and flagging $64m in potential legal claims. The dispute centres on a planned €50m investment by Porton into a new SlovenianFacilityintended to support Novartis’s European manufacturing footprint. According to …
Pharmaceutical companies are trapped in a paradox: the more sophisticated their products become, the more antiquated their commercial models remain. Take Pfizer’s rollout of Abrysvo, its respiratory syncytial virus (RSV) vaccine for older adults. Despite a strong clinical profile, the drug’s first-year sales of …
Yuhan Corporation is South Korea’s oldest listed drugmaker, founded in 1926; it has pivoted from branded generics to high-Marginactive pharmaceutical ingredients (APIs) and contract development and manufacturing organisation (CDMO) services. The Seoul-based group operates two dedicated API plants in Incheon and Daejeon, certified by …
Ipsen is a mid-cap French biopharmaceutical company specializing in rare disease therapies and specialty care products. With aMarket Capitalisationof approximately €9.2bn (as of May 2026), Ipsen generates 45% of itsRevenuefrom the United States and 30% from Europe, with a strategic focus on oncology, neuroscience, …
The pharmaceutical industry’s commercial teams have long grappled with a paradox: despite annual marketing budgets exceeding $30bn in the U.S. alone, the average share of voice—a proxy for engagement—remains stubbornly low. Studies suggest that over 60% of healthcare professionals (HCPs) ignore generic outreach, while …
Bristol Myers Squibb (NYSE: BMY) is quietly evaluating Houston as the site for a $1bn manufacturing campus—a sign that Big Pharma is increasingly betting on the American South and Sun Belt for critical production capacity. The Generation Park district, a 1,700-acre mixed-use development northeast …
ImmunityBio Inc (NASDAQ: IMBY) has secured a Prescription Drug User Fee Act (PDUFA) target action date of August 11 for its supplementalBiologicsLicense Application (sBLA) seeking to expand Anktiva (N-803) to first-line non-muscle-invasive bladder cancer (NMIBC). The FDA’s acceptance of the filing in late May …
Please wait processing your request...